325. Hereditary autoinflammatory syndrome Clinical trials / Disease details
Clinical trials : 7 / Drugs : 16 - (DrugBank : 6) / Drug target genes : 2 - Drug target pathways : 35
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04731103 (ClinicalTrials.gov) | February 2022 | 14/7/2020 | Inhibition of Reverse Transcription in Type I Interferon Mediated Neuropathology | Inhibition of Reverse Transcription in Type I Interferon Mediated Neuropathology | Aicardi-Goutières Syndrome | Drug: Abacavir (ABC);Drug: Lamivudine (3TC);Drug: Abacavir (ABC)+Lamivudine (3TC)+Zidovudine (AZT) | University of Edinburgh | NHS Lothian;Medical Research Council | Not yet recruiting | 3 Months | 15 Years | All | 24 | Phase 2 | United Kingdom |
| 2 | NCT02363452 (ClinicalTrials.gov) | September 10, 2015 | 15/1/2015 | Reverse Transcriptase Inhibitors in AGS | A Pilot Clinical Trial of Reverse Transcriptase Inhibitors in Children With Aicardi-Goutières Syndrome (AGS) | Aicardi-Goutières Syndrome (AGS) | Drug: Reverse transcriptase inhibitors: Zidovudine, Lamivudine, Abacavir | Assistance Publique - Hôpitaux de Paris | NULL | Completed | 1 Month | 17 Years | All | 11 | Phase 2 | France |